VERA NASDAQ
Vera Therapeutics, Inc.
1W: -2.1%
1M: -13.0%
3M: -15.1%
YTD: -41.8%
1Y: +0.3%
3Y: +189.4%
5Y: +73.5%
$29.82
+1.51 (+5.35%)
Weekly Expected Move ±8.1%
$23
$26
$28
$30
$33
Credit Risk of going bust: lower than 62% of companies Debt: 3.6% of company value Bonds: none of note held by US funds details ▾
Of US companies ranked in the safest four tenths, about 1 in 3,500 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $0.13 (down 99.5%), Vera Therapeutics, Inc. would be worth roughly what it owes.
Total debt $75.2M against a stock market value of $2.04B.
Distance to default 6.46 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $37.6M (short-term plus half of long-term), stock volatility 61.0%; Altman Z'' -1.67. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
If the stock fell to about $0.13 (down 99.5%), Vera Therapeutics, Inc. would be worth roughly what it owes.
Total debt $75.2M against a stock market value of $2.04B.
Distance to default 6.46 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $37.6M (short-term plus half of long-term), stock volatility 61.0%; Altman Z'' -1.67. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Smart Money Score
Moderate
50
Insider—
Congress—
ETF Holdings—
Key Statistics
Market Cap$2.0B
52W Range23.05-56.05
Volume1,170,797
Avg Volume2,257,084
Beta0.95
Dividend—
Analyst Ratings
Company Info
CEOMarshall Fordyce
Employees361
SectorHealthcare
IndustryBiotechnology
IPO Date2021-05-14
Websiteveratx.com
2000 Sierra Point Parkway
Brisbane, CA 94005
US
Brisbane, CA 94005
US
650 770 0077
About Vera Therapeutics, Inc.
Vera Therapeutics, Inc. is a clinical-stage biotechnology company focused on the development and commercialization of treatments for significant immunological disorders, primarily within the United States. Their leading therapeutic candidate is atacicept, a fusion protein that patients self-administer as a subcutaneous injection. This drug is currently undergoing Phase IIb clinical trials to treat immunoglobulin A nephropathy. The company is also advancing MAU868, a monoclonal antibody in Phase 2 clinical development, designed to combat BK viremia infections. Founded in 2016 and based in Brisbane, California, the organization operated as Trucode Gene Repair, Inc. until it rebranded to Vera Therapeutics, Inc. in April 2020.
Latest News
Most shorted stocks on Wall Street
Will Vertex's Kidney Disease Pipeline Be a New Growth Engine?
CoreWeave’s Vera Rubin Lead Comes Down to Speed, Power, and Scale - MarketBeat
Vera Therapeutics (VERA) Says TRUTAKNA Met All Phase III Endpoints
Vera Therapeutics (VERA) Says TRUTAKNA Met All Phase III Endpoints - Yahoo Finance
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Fordyce Marshall | S-Sale | 18,500 | $37.00 | 2026-09-15 |
| Fordyce Marshall | S-Sale | 18,500 | $35.12 | 2026-09-02 |
| Boman Nancy Lee | A-Award | 44,987 | — | 2026-08-03 |
| Boman Nancy Lee | A-Award | 63,011 | $32.23 | 2026-08-03 |
| Boman Nancy Lee | 0 | — | 2026-08-03 |